Russell Barton
Chief Operating Officer at ACUMEN PHARMACEUTICALS, INC.
Net worth: 392 311 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michela Gallagher | M | - |
AgeneBio, Inc.
 AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | 16 years |
| Daniel O'Connell | M | 54 | 18 years | |
| Steve Reynolds | M | - | 3 years | |
| Derek Meisner | M | 53 | 2 years | |
| Kimberlee Drapkin | F | 55 | 2 years | |
| Charles I. Clarvit | M | 68 |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | 11 years |
| Matthew Zuga | M | 58 | 3 years | |
| Nathan Fountain | M | 61 | 3 years | |
| Jeffrey Ives | M | 73 | 10 years | |
| Sean Stalfort | M | 54 | 6 years | |
| Laura Stoppel | M | 38 | 4 years | |
| Derrell Porter | M | 53 | 1 years | |
| Siew Tin Gan | F | - | - | |
| Ronald M. Nordmann | M | 82 |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | 11 years |
| Jasna Jerecic | M | - | - | |
| Amber Dilley | F | - | 3 years | |
| Julie Bockenstette | F | - | - | |
| Kathleen Pierce | F | - | - | |
| Kasey Spencer | M | - | - | |
| Rod Dowler | M | - |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | - |
| Kenneth Payie | M | - |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | - |
| Karen Ashe | F | - |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | - |
| Janice Hitchcock | M | - | 6 years | |
| Alexandria Braun | F | - | 2 years | |
| Eric Siemers | M | 68 | 6 years | |
| Jim Doherty | M | 56 | - | |
| Darryle Schoepp | M | - |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | - |
| Robyn Moxon | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Grant A. Krafft | M | - | 24 years | |
| William F. Goure | M | - | 15 years | |
| Jeffrey Sevigny | M | 55 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 31 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Russell Barton
- Personal Network
